BioCentury | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

...meeting in Madrid. SEL-212 comprises pegsiticase (SEL-037), which is a pegylated uricase, co-administered with SVP-Rapamycin (SEL-110...
BioCentury | Oct 5, 2018
Preclinical News

Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

...Selecta Biosciences Inc. (NASDAQ:SELB) showed its SVP-Rapamycin nanoparticles co-administered with an adeno-associated viral (AAV) vector-mediated transgene...
...and cellular immune responses. Selecta has two SVP-Rapamycin combination products in the clinic. SEL-403 -- SVP-Rapamycin...
...pediatric. Kishimoto said Selecta plans to submit an IND by the end of 2019. Mary Romeo SVP-Rapamycin (SEL-110) Genethon Selecta...
BioCentury | Apr 13, 2018
Clinical News

Selecta reports additional Phase II data for gout combo

...gout. SEL-212 is a non-immunogenic therapy comprising pegsiticase (SEL-037), a pegylated uricase, co-administered with SVP-Rapamycin (SEL-110...
...0.05, 0.08, 0.1, 0.125 and 0.15 mg/kg SVP-Rapamycin, as well as both pegsiticase doses without SVP-Rapamycin...
...target: Uric acid Description: Non-immunogenic therapy comprising pegsiticase (SEL-037), a pegylated uricase, co-administered with SVP-Rapamycin (SEL-110...
BioCentury | Jan 4, 2018
Translation in Brief

RNA replaces enzymes

...Anc80-synMUT, a MUT DNA gene therapy, in preclinical testing for MMA. Selecta also has SVP-Rapamycin (SEL-110...
BioCentury | Nov 10, 2017
Clinical News

Selecta's gout combo lacks longer-term efficacy in Phase II trial

...gout. SEL-212 is a non-immunogenic therapy comprising pegsiticase (SEL-037), a pegylated uricase, co-administered with SVP-Rapamycin (SEL-110...
...0.05, 0.08, 0.1, 0.125 and 0.15 mg/kg SVP-Rapamycin, as well as both pegsiticase doses without SVP-Rapamycin...
...target: Uric acid Description: Non-immunogenic therapy comprising pegsiticase (SEL-037), a pegylated uricase, co-administered with SVP-Rapamycin (SEL-110...
BioCentury | Nov 8, 2017
Clinical News

Selecta shares halved on gout combo readout

...treat chronic, severe gout. The therapy is a non-immunogenic combination of pegsiticase (SEL-037) and SVP-Rapamycin (SEL-110...
...0.05, 0.08, 0.1, 0.125 and 0.15 mg/kg SVP-Rapamycin, as well as both pegsiticase doses without SVP-Rapamycin...
...Pegsiticase is a pegylated uricase, and SVP-Rapamycin is a nanoparticle encapsulating the immunomodulator rapamycin. Jaime De Leon pegsiticase SEL-037 SEL-110 SEL-212 SVP-Rapamycin Selecta...
BioCentury | Jun 26, 2017
Financial News

Selecta prices $50M private placement

...start Phase III testing of SEL-212 , a non-immunogenic combination of pegsiticase (SEL-037) and SVP-Rapamycin (SEL-110...
...vs. pegsiticase alone in an ongoing Phase II study (see BioCentury Extra, June 15) . Julian Zhu SEL-037 SEL-110 SEL-212 SVP-Rapamycin Selecta Uric...
BioCentury | Jun 23, 2017
Clinical News

Selecta reports Phase II data for SEL-212 to treat gout

...50%). SEL-212 is a non-immunogenic therapy comprising pegsiticase (SEL-037), a pegylated uricase, co-administered with SVP-Rapamycin (SEL-110...
...patients in the SEL-212 arm who received the minimum effective dose of 0.4/0.08 mg/kg SEL-212 pegsiticase/SVP-Rapamycin...
...target: Uric acid Description: Non-immunogenic therapy comprising pegsiticase (SEL-037), a pegylated uricase, co-administered with SVP-Rapamycin (SEL-110...
BioCentury | Jun 15, 2017
Clinical News

Selecta rises on Phase II gout readout

...to start a Phase III trial of the non-immunogenic combination of pegsiticase (SEL-037) and SVP-Rapamycin (SEL-110...
...were infusion reactions. Four were in patients receiving pegsiticase alone or the lowest dose of SVP-Rapamycin...
...a case of cholecystitis, was not related to treatment. Pegsiticase is a pegylated uricase, and SVP-Rapamycin...
BioCentury | May 19, 2017
Clinical News

Selecta's gene therapy improves survival in MMA mice

...Eye and Ear (Boston, Mass.). The company intends to combine the vector with its SVP-Rapamycin (SEL-110...
Items per page:
1 - 10 of 15